JP2019514855A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514855A5
JP2019514855A5 JP2018551137A JP2018551137A JP2019514855A5 JP 2019514855 A5 JP2019514855 A5 JP 2019514855A5 JP 2018551137 A JP2018551137 A JP 2018551137A JP 2018551137 A JP2018551137 A JP 2018551137A JP 2019514855 A5 JP2019514855 A5 JP 2019514855A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weight
pharmaceutically active
binding polypeptide
active binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018551137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514855A (ja
JP7224917B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/057775 external-priority patent/WO2017167997A1/en
Publication of JP2019514855A publication Critical patent/JP2019514855A/ja
Publication of JP2019514855A5 publication Critical patent/JP2019514855A5/ja
Priority to JP2023017273A priority Critical patent/JP7496906B2/ja
Application granted granted Critical
Publication of JP7224917B2 publication Critical patent/JP7224917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018551137A 2016-03-31 2017-03-31 組成物 Active JP7224917B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023017273A JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163178.3 2016-03-31
EP16163178 2016-03-31
PCT/EP2017/057775 WO2017167997A1 (en) 2016-03-31 2017-03-31 Compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017273A Division JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Publications (3)

Publication Number Publication Date
JP2019514855A JP2019514855A (ja) 2019-06-06
JP2019514855A5 true JP2019514855A5 (https=) 2020-05-14
JP7224917B2 JP7224917B2 (ja) 2023-02-20

Family

ID=55646428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018551137A Active JP7224917B2 (ja) 2016-03-31 2017-03-31 組成物
JP2023017273A Active JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023017273A Active JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Country Status (10)

Country Link
US (2) US10772839B2 (https=)
EP (1) EP3435982A1 (https=)
JP (2) JP7224917B2 (https=)
KR (1) KR102376369B1 (https=)
CN (2) CN117243904A (https=)
AU (2) AU2017240190A1 (https=)
CA (2) CA3019482A1 (https=)
IL (1) IL261792B (https=)
SG (1) SG11201807402PA (https=)
WO (2) WO2017167997A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122787A1 (en) * 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
DK3277719T3 (da) 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
HK1250011A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 具有蛋白酶可切割接头的肽构建体
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
EP3519438A1 (en) * 2016-09-30 2019-08-07 VHsquared Limited Compositions
EP3554342B1 (en) 2016-12-14 2024-07-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN113490686B (zh) 2019-01-07 2025-02-18 拜科托莱夫股份有限公司 病原体结合蛋白
WO2020243393A1 (en) * 2019-05-30 2020-12-03 Vta Labs, Llc Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021233296A1 (zh) * 2020-05-18 2021-11-25 深圳市塔吉瑞生物医药有限公司 大环化合物的固体形式及其制备和用途
CN113768051B (zh) * 2020-06-09 2024-03-19 中粮营养健康研究院有限公司 饲料添加剂及其制备方法和其在饲料中的应用以及替抗饲料
GB202017863D0 (en) * 2020-11-12 2020-12-30 Intract Pharma Ltd Novel compositions
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010126A (en) 1934-03-19 1935-08-06 Frank L Mclaughlin Measuring and dispensing can
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
ATE234855T1 (de) * 1993-09-20 2003-04-15 Anadis Ltd Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
CN1116898C (zh) * 2000-02-21 2003-08-06 湖北楚冠实业股份有限公司 一种口服免疫球蛋白制剂及其制备方法
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
MX2007006086A (es) * 2004-11-25 2007-07-11 Unilever Nv Anticuerpos de cadena pesada y de dominio.
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
US20080026820A1 (en) * 2006-07-05 2008-01-31 Aruze Gaming America, Inc. Slot machine and playing method thereof
WO2008031770A2 (en) 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
US20080145420A1 (en) * 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
JP5966202B2 (ja) * 2007-02-20 2016-08-10 アラガン ファーマシューティカルズ インターナショナル リミテッド 安定な消化酵素組成物
EP2079456B1 (en) * 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2009037264A2 (en) 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN101964403A (zh) 2009-07-23 2011-02-02 比克国际(天津)有限公司 一种电池组的封装方法及电池组
US20130012916A1 (en) 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
CA2792862C (en) 2010-03-10 2018-03-06 Incube Labs, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
ES2688591T3 (es) 2011-03-28 2018-11-05 Ablynx N.V. Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
WO2014030049A2 (en) * 2012-08-21 2014-02-27 Glaxo Group Limited Compositions comprising a single variable domain and camostat mesylate (cm)
JP6541581B2 (ja) 2013-03-15 2019-07-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 低濃度抗体製剤
WO2015058173A1 (en) 2013-10-18 2015-04-23 Abbvie Inc. Stable solid units and methods of making the same
EP3142645A4 (en) * 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3026012B1 (fr) * 2014-09-23 2017-12-01 Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique
DK3277719T3 (da) * 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物

Similar Documents

Publication Publication Date Title
JP2019514855A5 (https=)
US11090269B1 (en) Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US20100330129A1 (en) Gastroresistant Pharmaceutical Formulations Containing Rifaximin
JP2016164170A (ja) プロトンポンプ阻害剤を含む制御放出組成物
CN108289848A (zh) 包含urat1的有效抑制剂的药物组合物
WO2006070781A1 (ja) 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法
CN109310642B (zh) 美沙拉嗪的口服药物组合物
JPH07223970A (ja) 消化管内適所放出製剤
CN103269691A (zh) 用于控制释放美沙拉嗪的口服药物片剂和其获得方法
WO2023047274A1 (en) Extended release pharmaceutical compositions of dydrogesterone
US20070122480A1 (en) Sustained release formulations
TWI688411B (zh) 腸溶錠
RU2738114C2 (ru) Пероральные фармацевтические композиции никотинамида
US20110086102A1 (en) Delayed release compositions
US20090028944A1 (en) Pharmaceutical compositions comprising mesalamine
CN113382720A (zh) 用于美沙拉嗪或其衍生物施用的固体口服药物组合物
EP3796908B1 (en) Controlled release propiverine formulations
CN101090738A (zh) 含有碱性药物或其盐的基质型缓释制剂及其制备方法
US20230181545A1 (en) Controlled-release pharmaceutical formulations for treatment of intestinal infections
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
WO2009047800A2 (en) Oral controlled release composition of carvedilol
EP2488173A1 (en) Delayed release compositions
CA2750611A1 (en) Chronotherapeutic pharmaceutical composition